These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 11062708

  • 1. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
    Alas S, Bonavida B, Emmanouilides C.
    Anticancer Res; 2000; 20(5A):2961-6. PubMed ID: 11062708
    [Abstract] [Full Text] [Related]

  • 2. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 3. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 4. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan 24; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
    Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S.
    Clin Cancer Res; 2006 Oct 01; 12(19):5809-16. PubMed ID: 17020988
    [Abstract] [Full Text] [Related]

  • 6. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
    Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH.
    J Clin Oncol; 2005 Feb 01; 23(4):694-704. PubMed ID: 15681517
    [Abstract] [Full Text] [Related]

  • 7. Rituximab therapy for indolent non-Hodgkin's lymphoma.
    Hagenbeek A, Czuczman MS, Ghielmini M, Herold M, Kimby E, Solal-Céligny P, Unterhalt M.
    Anticancer Drugs; 2002 Nov 01; 13 Suppl 2():S11-7. PubMed ID: 12710586
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 01; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ.
    J Clin Oncol; 2008 Jan 10; 26(2):196-203. PubMed ID: 18182662
    [Abstract] [Full Text] [Related]

  • 12. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
    Di Gaetano N, Xiao Y, Erba E, Bassan R, Rambaldi A, Golay J, Introna M.
    Br J Haematol; 2001 Sep 10; 114(4):800-9. PubMed ID: 11564066
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S, Emmanouilides C, Bonavida B.
    Clin Cancer Res; 2001 Mar 10; 7(3):709-23. PubMed ID: 11297268
    [Abstract] [Full Text] [Related]

  • 14. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI, Carney D, Seymour JF.
    Cancer; 2006 Jun 01; 106(11):2412-20. PubMed ID: 16649223
    [Abstract] [Full Text] [Related]

  • 15. Combination chemotherapy and rituximab.
    Czuczman MS.
    Anticancer Drugs; 2001 Jun 01; 12 Suppl 2():S15-9. PubMed ID: 11508932
    [Abstract] [Full Text] [Related]

  • 16. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB.
    Clin Cancer Res; 2008 Jul 15; 14(14):4650-7. PubMed ID: 18628480
    [Abstract] [Full Text] [Related]

  • 17. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
    Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS.
    Clin Cancer Res; 2008 Mar 01; 14(5):1550-60. PubMed ID: 18316580
    [Abstract] [Full Text] [Related]

  • 18. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD, Emmanouilides C, Benson DM, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7046-53. PubMed ID: 17145827
    [Abstract] [Full Text] [Related]

  • 19. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B, Vega MI.
    Drug Resist Updat; 2005 Dec 01; 8(1-2):27-41. PubMed ID: 15939340
    [Abstract] [Full Text] [Related]

  • 20. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
    Pagel JM, Laugen C, Bonham L, Hackman RC, Hockenbery DM, Bhatt R, Hollenback D, Carew H, Singer JW, Press OW.
    Clin Cancer Res; 2005 Jul 01; 11(13):4857-66. PubMed ID: 16000584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.